Drug Profile
LY 3007113
Alternative Names: LY-3007113Latest Information Update: 18 Feb 2014
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antineoplastics
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 18 Sep 2013 Discontinued - Phase-I for Cancer (late-stage disease) in USA (PO)
- 19 Dec 2011 Phase-I clinical trials in Cancer (late-stage disease) in USA (PO)
- 06 May 2005 Preclinical trials in Cancer in USA (PO)